ArticleJournal of epidemiology2026
The Claims Data Learning & Enhancing for Algorithm Refinement (CLEAR) Study: Overview of the Study Design and Baseline Profile.
Article in Journal of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Safety monitoring of bivalent, quadrivalent, and 9-valent human papillomavirus vaccination in Japan: The vaccine effectiveness, networking, and universal safety (VENUS) study.Human vaccines & immunotherapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medical claims data are increasingly used in epidemiological studies but are inadequately validated to ensure their reliability in identifying diseases. We developed the Claims data Learning & Enhancing for Algorithm Refinement (CLEAR) Study as a database platform to enable the systematic, low-cost implementation of validation studies in Japan. The CLEAR Study links routinely generated medical claims data from hospitals with diagnostic data (eg, laboratory data and diagnostic imaging reports) at the patient level. Using diagnostic data as the gold standard for disease identification, researchers can validate and refine their claims-based identification algorithms. Diagnostic data are collected as needed for each validation study, and data are linked using pseudonymized medical record numbers. Personal information is protected through the use of research identification numbers. To demonstrate the platform's feasibility, we collected data on respiratory syncytial virus (RSV) infections and intussusception cases. Eight hospitals have agreed to participate in the CLEAR Study, and three have completed claims data provision. We obtained data for 5,022 RSV infection cases with 25,920 diagnostic tests, and 1,450 intussusception cases with 561,984 diagnostic tests. We also analyzed the initial diagnostic data for 39,212 RSV infection cases and 439,088 intussusception cases, demonstrating that the database can be used to validate algorithms for these diseases. The CLEAR Study is a newly developed database platform in Japan that facilitates validation studies of claims data for various diseases. By promoting validation studies, this platform will help to improve the reliability of claims-based epidemiological studies and drug risk assessments in Japan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.